Hydrochlorothiazide

Pfizer has issued a voluntarily recall of certain lots of quinapril HCl/hydrochlorothiazide tablets and additional lots distributed by Greenstone due to high levels of a nitrosamine known to be carcinogenic in high doses.

Intensive treatment to a systolic BP target of 110 mm Hg to less than 130 mm Hg was associated with a 26% reduced risk for CV events in older adults with hypertension compared with standard BP management.

A label change for the diuretic hydrochlorothiazide has been approved to include a small risk for non-melanoma skin cancer, the FDA announced in a press release.

Despite guidelines recommending chlorthalidone over hydrochlorothiazide for hypertension, the drugs have similar effectiveness and chlorthalidone was associated with a significantly worse safety profile, according to research published in JAMA Internal Medicine.